报价延迟最少15分钟:2025/11/16 04:39 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.77 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-12.57/-1.74
|
|
企业价值
7.85M
|
| 资产负债 |
|
每股账面净值
-2.97
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/11/16 04:39 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. |
